The Department of Health & Human Services has released a final rule that would penalize healthcare providers who interfere with a patient’s access to, exchange or use of their electronic health information.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
Unpacking the Court: An Analysis of Recent Supreme Court Decisions
Two recent Supreme Court decisions, Trump v. United States and Loper Bright Enterprises v. Raimond, have broad implications for administrative authority and regulatory advocacy. Joseph Cantrell, JD, analyzes how these decisions may affect the relative power of the different branches of government.
Take Action to Modernize Prior Authorization & Streamline Access to Care
The reintroduction of the Improving Seniors’ Access to Care Act gives an opportunity to reduce administrative burden and undue delay of patient care imposed by prior authorization in Medicare Advantage plans. Contact your members of Congress today to urge them to pass this vital bill.

The ACR and CHEST Release 2 New ILD Guidelines
Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).
ACR Applauds Legislation to Reform Prior Authorization Policies
A new bill, the Improving Seniors’ Timely Access to Care Act, aims to streamline the prior authorization process. “The prior authorization process has become unmanageable for both doctors and patients. Insurer red tape imposes a significant burden on clinicians, leading to unnecessary and unclear delays, or even outright denials of patient care,” says ACR President…

CAR-T Cells: Are We Closer to Drug-Free Remission Than We Think?
Most Sunday mornings, I make myself an exceptional cup of pour-over coffee and sit down on my deck with the latest issue of the New England Journal of Medicine. I check out the image of the week. I read the case report with pen in hand, racing to diagnose the patient before the authors spill…
ACR Successfully Leads Coalition in AMA House of Delegates to Support Higher Pediatric Specialist Compensation
An ACR-led resolution that calls for Medicaid payment parity for pediatric specialists will become AMA policy.
Changes in the Rheumatology Workforce
Mannion et al. set out to describe the adult rheumatology workforce in the U.S. by measuring the number of rheumatologists and advanced practice providers entering and exiting the field and studying their demographics.

Ethics Forum: Regarding Chatbots in Rheumatology
Chatbots are not a new concept, but have recently gained popularity and traction. Launched in late 2022, ChatGPT (Chat Generative Pre-Trained Transformer) is a web-based platform designed to simulate interactive conversations and deliver real-time data. It has quickly become a tool that provides instantaneous information that can be more focused than a Google search.1 We,…

Methotrexate Shows Promise for Hand Arthritis
Methotrexate—an affordable, established drug for rheumatoid arthritis—may also be helpful for patients suffering from osteoarthritis (OA) of the hand, a recent study reports.1 Treatment of hand OA and inflammation with 20 mg of methotrexate for six months had a moderate, but potentially clinically meaningful, effect on reducing pain and stiffness in patients with symptomatic hand…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 244
- Next Page »